Decibel Announces Successful Closing of Private Placement
Decibel Cannabis Company Inc. (the "Company" or "Decibel") is excited to share the successful completion of a second tranche and the closing of its recent private placement. This transaction has solidified Decibel's position as a notable player in the premium cannabis sector, allowing the company to boost its growth trajectory significantly.
Details of the Private Placement
As part of the second closing, Decibel successfully issued 19,647,776 common shares at a price of $0.06 each, generating approximately $1,178,867. This follows the earlier closing where the company issued 33,503,864 shares, raising about $2,010,232. Remarkably, no finders' fees were incurred during either closing of the offering.
Utilization of Proceeds
The proceeds from this offering will play a crucial role in general working capital, enabling Decibel to effectively integrate AgMedica BioScience Inc., which was recently acquired. The infusion of funds positions Decibel to harness AgMedica's capabilities and streamline operations effectively.
Regulatory Compliance and Shareholder Participation
This offering is contingent upon obtaining all necessary regulatory approvals, including the final consent from the TSX Venture Exchange (“TSXV”). Notably, a portion of the newly issued shares is subject to a holding period expiring four months and one day after issuance, although shares allocated to company employees may be exempt.
Involvement of Company Insiders
During the course of this offering, several directors and officers participated by acquiring a total of 19,460,061 common shares across both closings. Their involvement qualifies as a “related party transaction” under Multilateral Instrument 61-101, which, due to regulations, does not require a formal valuation or minority shareholder approval.
Decibel's Growth Trajectory
Decibel is renowned for its commitment to delivering high-quality cannabis products. The company’s brand portfolio includes General Admission, Qwest, and Vox, which all resonate with consumers. Following its recent acquisition of AgMedica, Decibel has enhanced its production capabilities and product offerings, expanding its reach regionally and globally.
Strengthening Industry Position
The integration of AgMedica, known for its EU-GMP-certified production facility, is expected to augment Decibel’s market presence significantly. With three cultivation sites and a state-of-the-art processing and manufacturing center, Decibel is poised to lead the charge in high-quality, globally distributed cannabis products.
About Decibel Cannabis Company
Decibel aims to meet the evolving demands of consumers through innovation. By prioritizing excellence and quality, the company establishes a competitive edge in a rapidly growing market. Their expanding global strategy includes not only maintaining high domestic standards but also adhering to international benchmarks.
Frequently Asked Questions
What is Decibel Cannabis Company known for?
Decibel Cannabis Company is recognized for producing premium cannabis products with a commitment to quality and innovation.
How much funding did Decibel raise in the private placement?
Decibel raised approximately $1,178,867 in the second closing and $2,010,232 in the first closing of its private placement.
What will Decibel do with the proceeds from the offering?
The proceeds will be utilized for general working capital and to facilitate the integration of AgMedica BioScience Inc.
Who participated in the recent offerings?
Several directors and officers of the Company subscribed for a substantial number of common shares during both closings of the offering.
What is the importance of the TSX Venture Exchange's approval?
The approval from the TSX Venture Exchange is crucial for the offering as it ensures regulatory compliance for the securities issued.
